Pacific Biosciences Of California (PACB) EBIT Growth (3y) (2013 - 2026)
Pacific Biosciences Of California (PACB) EBIT Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | 3.16% |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 19.80% |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 6.17% |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 31.84% |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 24.88% |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 35.44% |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 9.04% |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 60.19% |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 13.06% |
| 10 | Pacific Biosciences Of California | 381.79 Mn | 144.92 Mn | 12.64 Mn | 15.21% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.21% |
| Mar 31, 2026 | 54.92% |
| Dec 31, 2025 | 22.08% |
| Sep 30, 2025 | 19.53% |
| Jun 30, 2025 | 12.94% |
| Mar 31, 2025 | -76.87% |
| Dec 31, 2024 | -33.25% |
| Jun 30, 2024 | -67.27% |
| Mar 31, 2024 | -34.14% |
| Dec 31, 2023 | -53.99% |
| Sep 30, 2023 | -50.55% |
| Jun 30, 2023 | -45.98% |
| Mar 31, 2023 | -40.77% |
| Dec 31, 2022 | -69.39% |
| Sep 30, 2022 | -38.46% |
| Jun 30, 2022 | -40.74% |
| Mar 31, 2022 | -37.02% |
| Dec 31, 2021 | -28.30% |
| Jun 30, 2021 | -20.00% |
| Mar 31, 2021 | -12.07% |